Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Journal of Cellular Physiology|September 11, 2014
Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytesJohn Charles Rotondo, Silvia Bosi, Cristian Bassi, et al.
Cell Death & Disease|May 13, 2021
Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesisEmi Dika, Elisabetta Broseghini, Elisa Porcellini, et al.
Frontiers in Genetics|May 1, 2013
miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAsLaura Lupini, Cristian Bassi, Manuela Ferracin, et al.
Molecular Cancer Therapeutics|October 20, 2021
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 ActivityTommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, et al.
Cell Death & Disease|March 29, 2025
Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferationTania Rossi, Martina Valgiusti, Maurizio Puccetti, et al.
Cancers|August 12, 2022
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted TherapyLauretta Levati, Cristian Bassi, Simona Mastroeni, et al.
Journal of Hematology & Oncology|September 17, 2016
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlationsGian Matteo Rigolin, Elena Saccenti, Cristian Bassi, et al.
Oncotarget|December 17, 2013
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patientsGian Matteo Rigolin, Elena Saccenti, Lara Rizzotto, et al.
Oncotarget|June 4, 2015
Absolute quantification of cell-free microRNAs in cancer patientsManuela Ferracin, Laura Lupini, Irene Salamon, et al.
Oncotarget|April 22, 2017
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessGian Matteo Rigolin, Luca Formigaro, Maurizio Cavallari, et al.
Pageof 5